Healthcare services: providers and payors

The one mechanism that explains almost everything

If there's a single concept that unlocks most of the interview questions asked about hospitals, physician groups, home health agencies, and health insurers, it's this: almost nobody in this part of the sector sets their own price the way a normal business does. A provider gets paid what a payor's contract, or a government program's fee schedule, says it gets paid for a given service. A payor's entire business is built around managing the gap between the premiums it collects and the claims it has to pay out on behalf of the people it covers. This third-party-payment structure, called reimbursement, is the organizing mechanism behind the entire providers-and-payors half of the healthcare sector, and interviewers use it constantly to test whether a candidate actually understands the sector or has just memorized that "healthcare is complicated."

Volume and rate: the two levers of provider revenue

Every dollar of revenue a healthcare provider earns can be decomposed into exactly two components: how many units of care it delivered, and how much it got paid per unit. Volume is the number of patients seen, procedures performed, or admissions handled. Rate is the reimbursement received per unit of that activity, which varies depending on which payor, government or commercial, is footing the bill and what that payor's specific contract or fee schedule says.

This decomposition matters because the two levers behave completely differently and carry very different implications for how durable a given period of revenue growth actually is. Growth driven by volume, treating more patients through added capacity, added locations, or population growth in a service area, tends to be a repeatable, structural driver that continues into future periods as long as the underlying demand and capacity keep growing. Growth driven by rate, negotiating a higher reimbursement rate with a major payor or benefiting from a government fee schedule update, is often closer to a one-time step change: once the new rate is locked in, it doesn't keep compounding on its own the way added patient volume does, and a subsequent period without a further rate increase can look like slowing growth even though nothing about the underlying business changed.

Interviewers ask candidates to decompose provider revenue growth into these two pieces specifically because so many candidates default to citing a single blended growth number without asking which lever is actually driving it. A private equity-backed physician practice platform, for instance, might show strong overall revenue growth that's actually coming mostly from acquiring additional practices (adding volume through consolidation) rather than from organic growth at existing locations, and a sharp candidate will ask to see the two pieces separately before concluding anything about the underlying business's health.

Providers: hospitals, physician groups, and home health

Providers deliver patient care directly, and the sub-sector spans a wide range of business sizes and models. A large hospital system operates capital-intensive facilities with high fixed costs and complex payor-mix dynamics across many different service lines. A physician practice group is typically less capital-intensive, with labor, physician and staff compensation, as the dominant cost, and it's a common target for the roll-up strategy described below. Home health and hospice agencies sit somewhere in between, delivering care outside a traditional facility and depending heavily on payor and government program reimbursement policy for their specific services.

Payor mix, the proportion of a provider's patients covered by government programs versus commercial insurance, is one of the first things a banker asks about when evaluating a provider, because commercial payors and government programs typically reimburse at different rates for the same service, and a shift in payor mix, even with volume held constant, can move a provider's revenue and margin meaningfully. A provider serving a patient population weighted more heavily toward one payor type carries different economics and different risk than one with a different mix, even if the two treat a similar number of patients.

Payors: premiums, claims, and the medical loss ratio

Payors, meaning health insurers and managed care organizations, run on a different but related mechanism: they collect premiums from the people, employers, or government programs they cover, and they pay out claims on behalf of those covered members when care is delivered. The core relationship between the two, how much of premium revenue actually goes back out the door as claims, is called the medical loss ratio, and it's the single most important metric in evaluating a payor's underlying profitability.

A payor's business, in this framework, isn't fundamentally about selling more insurance the way a normal business sells more product. It's about pricing risk accurately: setting premiums high enough to cover the claims a covered population is expected to generate, plus administrative costs and a margin, without pricing so high that the payor loses membership to a competitor. A payor that consistently underprices its risk will see its medical loss ratio climb as claims outpace premiums, eroding profitability, while a payor that overprices risk may hold profitability but lose membership growth over time. This tension, between growing membership and maintaining pricing discipline, is the central strategic question at almost every payor, and it's a common thread in interview questions that ask you to evaluate a payor's reported results.

Fee-for-service versus value-based care

Reimbursement itself isn't a single, uniform mechanism, and it's worth knowing the two broad models that show up in interviews. Under fee-for-service, a provider gets paid for each individual service it delivers, a visit, a test, a procedure, regardless of the patient's overall health outcome. This aligns a provider's revenue directly with volume, which is straightforward but has been criticized for potentially rewarding the quantity of care delivered rather than its quality or necessity.

Under value-based care arrangements, a provider's payment is tied at least partly to patient outcomes or to managing the total cost of a patient's care, rather than purely to the volume of services delivered. The specific structures vary widely, from bonus payments for hitting quality benchmarks to arrangements where a provider group takes on some financial responsibility for a patient population's total cost of care. The strategic and financial appeal, at least in theory, is aligning incentives around health outcomes rather than volume, though it also shifts a meaningful amount of financial risk onto the provider that fee-for-service reimbursement does not. Recognizing which reimbursement model a given provider or contract operates under changes how you'd model its revenue and its risk, and interviewers sometimes probe whether a candidate understands that the two models create very different incentive structures rather than just different payment mechanics.

Roll-ups and multiple arbitrage

The provider sub-sector, especially physician practice groups, home health, and other services businesses with many small, independently owned operators, is a favorite target for the roll-up strategy, where a sponsor or platform company acquires a series of smaller practices and integrates them into a single larger, more efficient operation. Two distinct sources of value creation drive this strategy. Multiple arbitrage captures the fact that a larger, more institutionalized platform typically trades at a higher multiple than any of the small, individually owned practices that make it up, simply because a bigger, more diversified, more professionally run business is perceived as lower risk by a subsequent buyer. Operational synergies capture the real cost savings available from consolidating back-office functions, billing, scheduling, payor contracting, and administration, across practices that previously each ran their own separate, smaller-scale versions of the same overhead.

This roll-up dynamic overlaps heavily with financial sponsors work, since private equity firms are the most common sponsors of these platforms, and the leveraged buyout mechanics underneath a roll-up thesis are the same core mechanics used anywhere else sponsors build a platform through add-on acquisitions, covered in the financial sponsors group guide. The specific deal structures used to actually execute these transactions, and how they differ from the licensing and milestone-based deals used in biopharma, are covered in healthcare deal structures: licensing and milestones.

Local regulation adds another layer

Provider consolidation also runs into a regulatory layer that doesn't really exist elsewhere in the sector: state-level rules that can restrict whether and how a hospital or other facility can expand, add capacity, or change ownership in a given area, on top of the antitrust review any large enough merger would face anyway. This adds a genuinely local dimension to provider M&A that a national roll-up strategy has to account for market by market, since the regulatory friction to consolidating two hospital systems in the same region can be very different from the friction to combining two systems in different states. The fuller regulatory picture, including how antitrust review of provider consolidation specifically watches local market concentration, is covered in regulatory risk in healthcare M&A.

Why this all matters for interviews

A candidate who can walk through the volume-and-rate decomposition, explain the medical loss ratio in a sentence, and distinguish fee-for-service from value-based care without prompting has covered most of what a services and payors interview actually tests. The concepts aren't individually difficult, but interviewers use them because they reliably separate a candidate who has done real preparation from one who is relying on generic banking knowledge and hoping the healthcare-specific vocabulary doesn't come up. Being fluent here is also directly useful for the fit question, since a genuine, specific interest in how reimbursement shapes provider and payor behavior is a far stronger answer than a generic statement about wanting to help patients, a distinction covered in how to answer why healthcare.

Practice question

How would you think about a hospital system's revenue growth if you only had one year of financial data?

I'd want to decompose the growth into volume and rate before drawing any conclusion, because the two drivers mean very different things for how durable that growth actually is. Volume growth, meaning more patients treated, more procedures performed, or more locations added, tends to be a structural driver that can continue compounding if the underlying demand and capacity keep growing. Rate growth, meaning a higher reimbursement rate negotiated with a payor or a government fee schedule update, is often closer to a one-time step change that doesn't keep compounding on its own in future periods. If I only had one year of data, I'd ask specifically whether the reported revenue growth came from a renegotiated payor contract, a shift in payor mix toward higher-reimbursing patients, or genuine growth in patients treated, because a hospital system that looks like it's growing quickly might really be showing the effect of a rate increase that won't repeat next year. I'd also want to know the system's payor mix, since a shift toward a payor type that reimburses at a different rate can move revenue even with patient volume held completely flat. Without separating these pieces, a single blended growth number tells you very little about whether the underlying business is actually getting healthier.

What the interviewer is listening for: whether you reach for the volume-and-rate framework on your own, without being prompted, and whether you can explain concretely why the two drivers imply different things about sustainability. A candidate who just says "I'd look at revenue growth" without decomposing it hasn't shown sector-specific judgment.